Sucraid (sacrosidase)
Digestive Enzymes Oral Solution, Oral
Last reviewed · Source: First Databank (FDB) drug data
Overview
Sacrosidase is a synthetic form of sucrase, an endogenous enzyme that hydrolyzes sucrose into glucose and fructose.
Sacrosidase is a synthetic form of sucrase (beta,d-fructofuranoside fructohydrolase), an endogenous enzyme that hydrolyzes sucrose into glucose and fructose. Commercially available sacrosidase is derived from baker's yeast (Saccharomyces cerevisiae). Sacrosidase consists of 513 amino acids and has an apparent molecular weight of 100,000 (66,000-116,000) as the glycosylated monomer.
The enzyme reportedly also exists as a dimer, tetramer, and octomer in solution with molecular weights ranging from 100,000-800,000.
Potency of sacrosidase is expressed in international units (IU, units); each mg of sacrosidase is equivalent to approximately 6.5-8.75 units. Sacrosidase reportedly is approximately 100 times as potent as endogenous sucrase on a per-mL basis.
Sacrosidase functions as replacement therapy for endogenous sucrase in patients with congenital sucrase-isomaltase deficiency (CSID). CSID is a chronic, autosomal recessive, inherited disease of the small intestine that usually is characterized by a complete or almost complete lack of endogenous sucrase activity, a varying decrease in isomaltase activity, a moderate decrease in maltase activity, and normal lactase concentrations. Sucrase catalyzes the hydrolysis of the disaccharide sucrose to glucose and fructose, while isomaltase breaks down disaccharides from starch to simple sugars.
In the absence of endogenous sucrase, sucrose is not metabolized. Unhydrolyzed sucrose and starch are not absorbed in the large intestine and their presence in the intestinal lumen may lead to osmotic retention of water and loose stools or diarrhea. In addition, bacterial fermentation of unabsorbed sucrose in the intestine produces increased amounts of hydrogen, methane, and water, resulting in excessive gas, bloating, abdominal cramps, nausea, and vomiting.
Sacrosidase does not contain isomaltase and does not catalyze the hydrolysis of starch.
Generic name: sacrosidase
Drug class: Digestive Enzymes
Therapeutic class: Gastrointestinal Therapy Agents
Reference product & biosimilars
No reference, biosimilar or interchangeable associated with this drug.
Today’s intelligence on Sucraid
Indications
The following indications are listed for Sucraid:
- Congenital Sucrase-Isomaltase Deficiency
Also known as: Congenital Sucrose Intolerance, Sucrase-Isomaltase Deficiency.
Dosing
Dosage of sacrosidase is expressed in international units (IU, units). Each mL of sacrosidase contains 8500 units of the enzyme.
For use as oral replacement therapy of the genetic deficiency in sucrase that is part of congenital sucrase-isomaltase deficiency, the recommended dosage of sacrosidase for patients weighing 15 kg or less is 8500 units (1 mL using the measuring scoop provided or 22 drops from the Sucraid(R) container tip) administered with each meal or snack. For patients weighing more than 15 kg, the recommended dosage of sacrosidase is 17,000 units (2 mL using the measuring scoop provided or 44 drops from the Sucraid(R) container tip) administered with each meal or snack.
Sacrosidase is administered orally with each meal or snack.
The solution of sacrosidase is diluted with 60-120 mL of water, milk, or infant formula. These diluents should not be warmed or heated before or after the addition of sacrosidase because potency of the drug is likely to be decreased by heat; instead, sacrosidase should be administered cold or at room temperature.
Administration of sacrosidase with food and/or milk appears to diminish the degradation of the enzyme by intragastric pepsin. The manufacturer recommends that half of each dose be given at the beginning of each meal or snack, and the other half at the end. Fruit juice should neither be consumed with sacrosidase nor used as a diluent because the acidity of the juice may reduce the activity of the enzyme.
| Drug label | Dosing type | Instructions |
|---|---|---|
| Sucraid 8,500 Unit/Ml Soln | Maintenance | Take 1 milliliter (8,500 unit) by oral route before and after each meal or snack. |
| Sucraid 17,000 Unit/2 Ml Soln | Maintenance | Take 1 milliliter (8,500 unit) by oral route before and after each meal or snack. |
No dosing information is available for this tab.
Drug interactions
There is no enhanced messaging for this drug.
There are no contraindication interactions for this drug.
There are no severe interactions for this drug.
There are no moderate interactions for this drug.
Contraindications
Known hypersensitivity to yeast, yeast products, or glycerin (glycerol).
There are no contraindication contraindications for this drug.
- Gastrointestinal obstruction
- Diabetes mellitus
Adverse reactions
Abdominal pain, vomiting, constipation, diarrhea, nausea, dehydration, headache, insomnia, and nervousness have been reported in clinical studies of up to 54 months' duration. Wheezing, probably associated with hypersensitivity to sacrosidase, has been reported in an asthmatic child who received sacrosidase. (See Warnings: Sensitivity Reactions, in Cautions.)
Rare or Very Rare
- Hypersensitivity drug reaction
- Wheezing
Less Frequent
- Abdominal pain with cramps
- Constipation
- Dehydration
- Diarrhea
- Headache disorder
- Insomnia
- Nausea
- Nervousness
- Polydipsia
- Vomiting
Rare or Very Rare
- Pruritus of skin
- Skin rash
Precautions
No enhanced messaging available.
Patients as young as 5 months of age have been treated with sacrosidase. Safety and efficacy of sacrosidase for use as oral replacement therapy of the genetic deficiency in sucrase that is part of congenital sucrase-isomaltase deficiency has been shown in a controlled study of principally pediatric patients.
Category C. (See Users Guide.) Sacrosidase is not absorbed intact into the systemic circulation and is not expected to cause fetal harm when administered to a pregnant woman or to affect reproductive capacity.
No enhanced messaging available.
No enhanced messaging available.
ICD codes
| Code | Type | Description |
|---|---|---|
| Congenital sucrase-isomaltase deficiency | ||
| E74.31 | ICD10CM | Sucrase-isomaltase deficiency |
ICD code information from First Databank (FDB).
Formulary status
Search health-plan coverage for this drug by ZIP code.
Choose the first character of a health plan name.
Last reviewed · Source: First Databank (FDB) drug data
On this page
Actions
Sign in to save favorites
Saving this drug requires a free Physicians Office Resource account.